Elevation Spine, Inc. Closes $11 Million Series B Financing

The company also announced the appointment of Donald Bossi and Bryson Hollimon, both of Technology Venture Partners, to its Board of Directors

Elevation Spine, Inc., the leading innovator of integrated-fixation spinal technologies, today announced the completion of its Series B Preferred Stock financing, totaling $11 million. The funding was led by Technology Venture Partners (“TVP”) and included participation from Mutual Capital Partners (“MCP”) and existing investors.

Elevation Spine also announced the appointment of Donald Bossi and Bryson Hollimon, both of Technology Venture Partners, to its Board of Directors.

Elevation Spine plans to use the proceeds from the financing to ramp the commercial production of Saber-C® as well as support product development of future product extensions of the company’s Saber® Technology platform of products.

“We are excited to support the Elevation Spine team at this critical growth stage. Saber Technology is an important advancement in spinal fusion technologies,” said Don Bossi of TVP. “It allows surgeons to access hard-to-reach areas of the spine more easily and with fewer procedural steps. This differentiated technology provides significant advantages to the surgeon and the patient over current technologies and has a very exciting future.”

Elevation Spine welcomes TVP and MCP to our team of investors,“ said Charles Gilbride, CEO of Elevation Spine. “This funding provides Elevation Spine with the capital to build out a full commercial team and expand the use of the Saber-C system. We will concurrently develop additional products utilizing Saber Technology to establish Saber as the leading platform technology in spinal fusions.”

About Elevation Spine

Hot this week

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."